Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 11/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | EP300 | Q09472 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2579492 | 0.84 | CNR2 (0.47) | CNR2KDM4ENPSR1CNR1BRD4 | |
| SCHEMBL9893013 | 0.80 | KDM4E (0.50) | CNR2KDM4ENPSR1CNR1BACE1 | |
| SCHEMBL16480410 | 0.80 | CASP1 (0.48) | CNR2KDM4ENPSR1CNR1CYP2C9 | |
| SCHEMBL9892143 | 0.79 | CNR2 (0.60) | CNR2KDM4ENPSR1CNR1ALOX5 | |
| SCHEMBL9893088 | 0.78 | PFKFB2 (0.46) | CNR2KDM4ENPSR1CNR1BACE1 | |
| SCHEMBL9891924 | 0.77 | CNR2 (0.47) | CNR2CNR1 | |
| SCHEMBL9103411 | 0.75 | ALDH1A1 (0.51) | CNR2KDM4ENPSR1CNR1 | |
| SCHEMBL9891935 | 0.75 | P2RX7 (0.53) | CNR2P2RX7KDM4E | |
| SCHEMBL9891951 | 0.73 | CNR2 (0.60) | CNR2P2RX7KDM4ECNR1 | |
| SCHEMBL9893076 | 0.71 | CNR2 (0.53) | CNR2P2RX7KDM4ECYP2C8CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CNR2 1/4885P2RX7 26/4885KDM4E 2527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.